Qube Research & Technologies LTD Ocugen, Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.36 - $0.57 $8,505 - $13,466	-23,625 Reduced 90.25%	2,552 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.4 - $0.62 $121,554 - $188,408	-303,885 Reduced 92.07%	26,177 $10,000
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $148,527 - $290,454	330,062 New	330,062 $178,000
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.87 $148,251 - $249,757	-133,560 Reduced 72.02%	51,881 $67,000
Q3 2022 Nov 14, 2022	SELL	$1.75 - $3.1 $545,114 - $965,631	-311,494 Reduced 62.68%	185,441 $330,000
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $909,391 - $1.71 Million	496,935 New	496,935 $1.13 Million

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.